1 – 4 of 4
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2020
- The will of Congress? Permissive regulation and the strategic use of labeling for the anti-influenza drug Relenza
- 2018
- Regulatory scientists' work has important ramifications for public health and should be open to public scrutiny
- 2017
- Why European and United States drug regulators are not speaking with one voice on anti-influenza drugs: regulatory review methodologies and the importance of 'deep' product reviews
- 2016
- Pharmaceutical Industry Off-label Promotion and Self-regulation: A Document Analysis of Off-label Promotion Rulings by the United Kingdom Prescription Medicines Code of Practice Authority 2003-2012.
